30 June 2016

Frontier Mining in off-take talks

Robert Tyerman

Kazakhstan-focused Frontier Mining is negotiating a £6 million funding with potential customers of its two million-tonne Benkala copper project.

Chairman and chief executive Erlan Sagadiev is in London discussing possible financing deals to take Benkala into production next summer and says an off-take deal, most likely with a Chinese group, is one of the options being considered.

AIM-quoted Frontier, which is merging with its 50 per cent local Benkala partner, Colville Intercorp, by granting Colville shares, argues Benkala, with a 0.55 per cent copper grade, would break even at copper prices less than a third of today's $6,600-plus a tonne. Sagadiev, an entrepreneur who built a bust dairy business into Asia Foodmaster, the continent's leading dairy products concern, points out Frontier also has several other projects in hand.

These include a potential copper deposit, with gold and molybdenum, at Baitimir, a 10,000 oz-a-year gold project at Koskuduk newly in production and Maminskoye, a gold project, where Frontier hopes to treble estimated resources from one million oz at 2.49 grammes of gold per tonne of ore to three million oz. Sagadiev says he hopes Maminskoye will start producing in 2013 with estimated production costs of $430 an ounce, against a current market price of nearly $1200 an ounce, and says the company is looking for new assets in Kazakhstan, Kyrgyzstan and Mongolia.

Sagadiev is the controlling shareholder in Frontier, which is re-domiciling itself from Delaware in the USA to the Cayman Islands, and says he is anxious to restore its former institutional following, while hinting at a first dividend in 2013 or 2014. The company lost $30.3 million (£20.2 million) last year on maiden revenues of $2.9 million, after a $25 million 'fair value adjustment' chiefly relating to outstanding loan notes, but analysts see profitability within the not-too distant future.

Floated at 15p six years ago, Frontier shares have been dismal performers. Now 5p, 1p up from their low, they value the company at £46 million and offer speculative recovery potential for the bold.

Tags: AIM, Dividend

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Omega investing in growth

Omega Diagnostics results looked positive and highlighted the progress being made in getting important new products to market. The investment to support those efforts will depress profits this year; but the market seems willing to look through this with Omega being a rare stock to be trading above its pre-Brexit level.

Stadium hit by profit warning

Stadium Group shares have been hit by a profit warning. This is a particular blow given the company’s progress in repositioning itself into a higher quality, design-led business.

Verona raises £42m to fund drug trials 

Verona Pharma (AIM: VRP) has raised an impressive £42 million net of costs which will fund phase II trials for its RPL554 compound. This drug targets severe respiratory diseases, in particular the 65 million worldwide sufferers from COPD (chronic obstructive pulmonary disease).

Income attractions at Belvoir

It’s fair to say that buy-to-let landlords have been under George Osborne’s cosh. He’s introduced a raised stamp duty rate and withdrawn higher-rate tax relief. However, Belvoir Lettings has seen little change in the market as far as its core lettings agency business is concerned. Furthermore, the shares have responded positively to a major acquisition which makes Belvoir the largest UK lettings agent.

Wincanton keeps on trucking

Wincanton CEO Adrian Colman feels his company is now back on an even keel after a period of fire-fighting. Debt has been brought under control, the pension deficit is being addressed, and onerous leases and contracts have been dealt with. A return to the dividend list illustrates these positive changes and the fact that management can now fully focus on growing the business.

VP maintains its reputation for quality  

Plant hire company VP continues to perform well against a mixed backdrop. Management said that the core infrastructure, housing and construction markets remained generally supportive and have offset weakness in oil and gas.

More News